查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024910

癌症單株抗體市場規模、佔有率、趨勢和預測：按抗體類型、藥物類型、應用、最終用戶和地區分類，2026-2034年

Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球癌症單株抗體市場規模為500億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到667億美元，2026年至2034年的複合年成長率（CAGR）為3.17%。目前，北美市場主導地位，預計2025年將佔據38.7%的市場。這主要得益於北美先進的醫療基礎設施、對創新治療方法的早期應用以及許多領先生物製藥公司的強大影響力。此外，高癌症發生率和有利的健保政策也進一步推動了市場成長。這些因素共同作用，使北美得以保持在癌症單株抗體市場的領先地位。

該市場的主要驅動力是複雜和難治性腫瘤類型的日益增多，這需要更精準、更俱生物標靶的治療方法。免疫療法作為腫瘤一線治療方案的日益普及，正在加速單株抗體藥物的臨床試驗和監管核准流程。此外，生物相似藥的興起擴大了新興市場獲得這些治療方法的機會，促進了其更廣泛的應用。抗體藥物偶聯物（ADC）和雙特異性抗體的持續創新也在提高治療的療效和特異性。產學合作的不斷加強正在加速治療方法的研發，而高所得國家的支持性醫療保險報銷機制也進一步提振了癌症單株抗體市場的前景。例如，2025年5月，瑞士洛桑路德維希癌症實驗室和台灣台北醫學大學的研究人員開發了一種新型單株抗體PLT012，該抗體靶向CD36——一種腫瘤利用其在富含脂質的微環境中抑制免疫反應的脂質轉運蛋白。 PLT012能夠抑制CD36並恢復免疫功能，在包括免疫療法抗藥性模型在內的肝癌模型中均展現出強大的抗腫瘤作用。 PLT012可單獨使用，也可與查核點抑制劑合併使用，進而重建腫瘤的免疫微環境。 PLT012已獲得美國食品藥物管理局（FDA）的孤兒藥資格認定，為治療疑難癌症提供了一種極具前景的新型代謝免疫療法。

在美國，癌症單株抗體市場的成長得益於強大的生物製藥創新生態系統，該系統得到了聯邦政府的大力資助和私營部門的投資支持。先進的臨床基礎設施加速了藥物從研發到上市的進程，進一步推動了市場發展。患者對藥物的高度認知以及精準診斷的普及促進了新治療方法的早期應用。此外，真實世界數據（REW）和人工智慧（AI）在藥物研發和患者分層中的日益融合，支持了更個人化的治療方法。美國FDA的加速核准流程，例如突破性療法和優先審評，進一步縮短了產品上市時間。國內生物技術公司之間的策略聯盟和許可協議也促進了單株抗體療法的競爭性發展。

癌症單株抗體市場趨勢

癌症發生率上升推動了對單株抗體的需求。

全球癌症發生率的持續上升是單株抗體市場成長的主要驅動力。世界衛生組織（WHO）預測，到2050年，全球新增癌症病例將超過3,500萬例，凸顯了對更安全、更有效治療方法的迫切需求。與化療等傳統治療方法不同，單株抗體可提供標靶治療，且副作用更少。這種以患者為中心的治療方法在改善治療效果的同時，也最大限度地減少了全身性不良反應。隨著腫瘤學家追求更個人化和精準的治療方法，單株抗體正成為現代腫瘤治療方法的重要組成部分。這一趨勢反映了生物製藥領域正朝著更具特異性和安全性的方向發展，這些藥物能夠應對複雜的疾病，進一步推動了單株抗體在癌症治療策略中的應用。

擴大經濟高效的生物類似單株抗體的應用

癌症單株抗體市場的關鍵趨勢是生物相似藥的日益普及。這些經濟高效的替代療法因其療效與原廠生技藥品相當且成本更低，正受到醫療專業人士的青睞。根據Avelere Health為生物相似藥委員會所做的一項分析顯示，預計到2025年，美國將有120萬名患者能夠獲得生技藥品的普及。這種經濟性在市場擴張中發揮著至關重要的作用，尤其是在醫療預算有限的地區。此外，生物技術的進步使得生產結構和性能與參考藥物高度相似的生物相似藥成為可能。隨著成本效益在全球醫療保健系統中日益受到重視，生物類似單株抗體有望在擴大治療覆蓋範圍方面發揮越來越重要的作用。

支持個人化醫療的技術進步

基因定序分析和目標基因選擇的技術進步正推動單株抗體市場向個人化醫療方向發生重大轉變。這些進步使得單株抗體能夠針對特定的基因標記，從而不僅在癌症治療中，而且在自體免疫疾病和發炎性疾病的治療中，都提高了其療效。基於個別基因譜最佳化治療方案能夠改善患者預後並減少副作用。全球研發投入的增加和醫療基礎設施的改善為這種精準醫療方法提供了支持。此外，這些創新使得單株抗體能夠在降低生產成本的同時，複製原廠生技藥品的治療特性。隨著醫療產業不斷優先考慮個人化治療方案，個人化單株抗體療法正成為全球醫療服務的核心趨勢。例如，BioNTech所進行的一項II期臨床試驗，將BNT111與半原廠藥合併使用，在對PD-(L)1抑制劑抗藥性的進行性黑色素瘤患者中取得了顯著療效。與以往數據相比，該治療方法提高了整體緩解率，且耐受性良好。 BNT111 利用尿苷 mRNA 標靶四種黑色素瘤抗原。該項目已獲得 FDA簡審類和孤兒藥資格認定。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球癌症單株抗體市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依抗體類型分類

  • 小鼠抗體
  • 嵌合體抗體
  • 人源化抗體
  • 其他

第7章 市場區隔：依藥物類型分類

  • Bevacizumab（Avastin）
  • Rituximab（Rituxan）
  • 曲妥珠單抗（Herceptin）
  • Cetuximab（愛必妥）
  • Panitumumab（Vectibix）
  • 其他

第8章 市場區隔：依應用領域分類

  • 乳癌
  • 血癌
  • 肝癌
  • 腦癌
  • 結腸癌
  • 其他

第9章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 藥局
  • 研究所
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Amgen Inc.
    • AbbVie Inc.（Abbott Laboratories）
    • AstraZeneca plc
    • Biocon Limited
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.（Roche Holding AG）
    • Genmab A/S
    • Merck & Co., Inc.
    • Pfizer Inc.
Product Code: SR112026A1955

The global cancer monoclonal antibodies market size was valued at USD 50.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 66.7 Billion by 2034, exhibiting a CAGR of 3.17% during 2026-2034. North America currently dominates the market, holding a significant market share of 38.7% in 2025. This is attributed to its advanced healthcare infrastructure, early adoption of innovative therapies, and strong presence of leading biopharmaceutical companies. High cancer incidence rates and favorable reimbursement policies further support market growth. These factors collectively contribute to North America's leading cancer monoclonal antibodies market share.

The market is primarily driven by the growing prevalence of complex and refractory tumor types, necessitating more precise and biologically targeted treatment modalities. Increased emphasis on immunotherapy as a frontline approach in oncology has accelerated clinical trials and regulatory pathways for monoclonal antibody-based drugs. Moreover, the rise of biosimilars has expanded access to these therapies in emerging markets, fostering broader adoption. Continuous innovation in antibody-drug conjugates and bispecific antibodies is also enhancing treatment efficacy and specificity. Expanding academic-industry collaborations are contributing to faster therapeutic development, while supportive reimbursement frameworks in high-income countries are further creating a positive cancer monoclonal antibodies market outlook. For instance, in May 2025, researchers from Ludwig Cancer Research (Lausanne, Switzerland) and Taipei Medical University (Taiwan) developed PLT012, a novel monoclonal antibody targeting CD36, a lipid transporter exploited by tumors to suppress immune responses in fat-rich microenvironments. PLT012 blocks CD36, restoring immune function and showing strong anti-tumor effects in liver cancer models, including immunotherapy-resistant cases. It works alone or with checkpoint inhibitors and rewires the tumor immune landscape. With FDA orphan drug status, PLT012 offers a promising new metabolic immunotherapy approach for difficult-to-treat cancers.

In the United States, the cancer monoclonal antibodies market growth is propelled by a strong biopharmaceutical innovation ecosystem supported by robust federal funding and private sector investment. The presence of advanced clinical infrastructure enables rapid progression from discovery to commercial availability, accelerating market momentum. High patient awareness and access to precision diagnostics promote early adoption of novel therapies. Additionally, the increasing integration of real-world evidence and artificial intelligence in drug development and patient stratification supports more personalized treatment regimens. The U.S. FDA's expedited approval pathways, including Breakthrough Therapy and Priority Review designations, further streamline product launches. Strategic partnerships and licensing agreements among domestic biotech firms also sustain competitive advancement in monoclonal antibody therapeutics.

CANCER MONOCLONAL ANTIBODIES MARKET TRENDS:

Rising Cancer Incidence Driving Demand for Monoclonal Antibodies

The steadily increasing prevalence of cancer globally is significantly contributing to the growth of the monoclonal antibodies market. According to the World Health Organization (WHO), over 35 million new cancer cases are projected by 2050, underscoring an urgent demand for safer and more effective therapies. Unlike traditional treatments such as chemotherapy, monoclonal antibodies offer targeted therapy with fewer side effects. This patient-centric approach enhances treatment outcomes while minimizing systemic harm. As oncologists seek more personalized and precise therapies, monoclonal antibodies have become an integral part of modern oncology treatment regimens. This trend reflects a shift toward biologics that can address complex diseases with higher specificity and safety, supporting their increasing adoption in cancer treatment strategies.

Growing Adoption of Cost-Effective Biosimilar Monoclonal Antibodies

A key cancer monoclonal antibodies market trend is the increasing use of biosimilars. These cost-effective alternatives to original biologic therapies are gaining popularity among healthcare professionals due to their comparable efficacy and reduced costs. An analysis by Avalere Health for the Biosimilars Council estimates that biosimilar access could enable 1.2 million U.S. patients to obtain biologic treatments by 2025. This affordability plays a pivotal role in market expansion, especially in regions with limited healthcare funding. Additionally, advancements in biotechnology have enabled the production of biosimilars that closely match the reference drugs in terms of structure and performance. As cost-efficiency becomes a critical consideration for healthcare systems globally, biosimilar monoclonal antibodies are expected to play an increasingly important role in expanding treatment access.

Technological Advancements Supporting Personalized Medicine

Technological progress in gene sequencing and target gene selection is fostering a significant shift toward personalized medicine in the monoclonal antibodies market. With these advancements, monoclonal antibodies can be engineered to target specific genetic markers, enhancing their effectiveness in treating not only cancers but also autoimmune and inflammatory diseases. The ability to tailor treatments based on individual genetic profiles improves patient outcomes and reduces adverse effects. This precision medicine approach is supported by increased R&D investments and improved healthcare infrastructure worldwide. Moreover, these innovations allow monoclonal antibodies to mimic the therapeutic properties of original biologics while being produced at lower costs. As the healthcare industry continues to prioritize individualized treatment protocols, personalized monoclonal antibody therapies are becoming a central trend in global healthcare delivery. For instance, BioNTech's Phase 2 trial of BNT111 combined with cemiplimab showed a significant response in patients with advanced, anti-PD-(L)1 refractory melanoma. The treatment improved overall response rates versus historical data and was well tolerated. BNT111 uses uridine mRNA and targets four melanoma antigens. The program holds FDA Fast Track and Orphan Drug designations.

CANCER MONOCLONAL ANTIBODIES INDUSTRY SEGMENTATION:

Analysis by Antibody Type:

  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
  • Others

Humanized antibodies stand as the largest antibody type in 2025, holding around 40.7% of the market. The humanized antibodies segment dominates the cancer monoclonal antibodies market due to its superior efficacy, reduced immunogenicity, and enhanced safety profile. By replacing most of the mouse antibody components with human sequences, humanized antibodies minimize the risk of adverse immune responses in patients, making them more suitable for repeated administration. These antibodies offer targeted treatment by binding specifically to cancer cell antigens, thereby improving therapeutic outcomes while limiting damage to healthy tissues. Additionally, their compatibility with human immune systems enhances pharmacokinetics and therapeutic effectiveness. The growing adoption of personalized medicine and advancements in genetic engineering further support the dominance of humanized antibodies in cancer treatment.

Analysis by Medication Type:

  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others

Trastuzumab (Herceptin) leads the market in 2025. The Trastuzumab (Herceptin) segment dominates the cancer monoclonal antibodies market due to its established efficacy in treating HER2-positive breast and gastric cancers. As one of the first targeted therapies approved for oncology, Herceptin has significantly improved survival rates in patients with aggressive tumors overexpressing the HER2 protein. Its widespread clinical adoption, proven long-term safety profile, and inclusion in standard cancer treatment protocols have cemented its leading position. Additionally, ongoing research has expanded its applications through combination therapies and biosimilar developments, enhancing its accessibility and affordability. The sustained clinical success of Trastuzumab continues to drive its dominance in the cancer monoclonal antibodies market.

Analysis by Application:

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others

Blood cancer leads the market with around 23.8% of market share in 2025. The blood cancer segment dominates the cancer monoclonal antibodies market due to the high effectiveness of monoclonal antibody therapies in treating hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. These cancers often exhibit specific surface antigens, making them ideal targets for antibody-based treatments like Rituximab and Daratumumab. Moreover, blood cancers generally have a more accessible cellular environment compared to solid tumors, enhancing therapeutic delivery and response rates. The increasing incidence of blood cancers globally, coupled with advancements in targeted therapy and the development of biosimilars, has further expanded patient access. As a result, the blood cancer segment continues to lead in terms of treatment demand and market share.

Analysis by End User:

  • Hospitals and Clinics
  • Pharmacies
  • Research Laboratories
  • Others

Hospitals and clinics lead the market with around 40.3% of market share in 2025. The hospitals and clinics segment dominates the cancer monoclonal antibodies market due to their central role in administering advanced oncology treatments and managing complex care protocols. These facilities are equipped with the necessary infrastructure, specialized staff, and diagnostic capabilities required for safe and effective monoclonal antibody therapy. Additionally, most monoclonal antibody treatments are administered intravenously, necessitating a clinical setting for proper dosage, monitoring, and management of potential adverse effects. The growing number of hospital-based cancer centers, increased patient footfall, and favorable reimbursement policies further reinforce the dominance of this segment. As a result, hospitals and clinics remain the primary channel for delivering cancer monoclonal antibody therapies.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 38.7%. North America dominates the cancer monoclonal antibodies market due to its advanced healthcare infrastructure, high adoption of innovative therapies, and strong presence of major pharmaceutical companies. The region benefits from significant investments in oncology research and favorable regulatory support for fast-track drug approvals. Additionally, rising cancer incidence, increased awareness about targeted therapies, and widespread availability of health insurance contribute to higher treatment uptake. Robust clinical trial activity and strategic collaborations between biotech firms and research institutions also fuel innovation and market expansion. These factors collectively position North America as the leading region in the global cancer monoclonal antibodies market. For instance, in March 2024, the FDA approved BeiGene's TEVIMBRA (tislelizumab) for adults with unresectable or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The Phase 3 RATIONALE 302 trial showed TEVIMBRA significantly improved overall survival over chemotherapy. This is BeiGene's first U.S. approval for TEVIMBRA. The PD-1 monoclonal antibody has also been approved in the EU and is under review for first-line use in ESCC and gastric cancers. Over 900,000 patients worldwide have received the drug to date.

KEY REGIONAL TAKEAWAYS:

UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS

In 2025, the United States held a market share of around 84.30% in North America. The United States cancer monoclonal antibodies market is expanding steadily, driven by a high burden of chronic diseases and advanced research capabilities in immunotherapy. The region benefits from significant investments in precision medicine and cutting-edge biotechnological tools, enabling the development of particular antibody-based cancer treatments. According to the American Cancer Society, over 2 Million new cancer cases are expected to be diagnosed in the US in 2025, with more than 618,000 deaths projected, further intensifying the demand for innovative monoclonal antibody therapies. Strong regulatory support for fast-tracking breakthrough therapies also contributes to the market's dynamism. Moreover, the presence of specialized academic institutions and translational research centers fosters innovation in monoclonal antibody development. Growing awareness of personalized treatment options is prompting patients and healthcare providers to favor biologics over conventional chemotherapy. The integration of real-world data into clinical trial design is enhancing therapy success rates and market penetration. Additionally, strategic collaborations between research entities and manufacturers are accelerating product pipelines. Increasing uptake of outpatient care and ambulatory infusion centers has further supported therapy accessibility, enhancing treatment continuity. Furthermore, the adoption of artificial intelligence in clinical oncology is optimizing patient stratification, thereby improving monoclonal antibody efficacy.

EUROPE CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS

The cancer monoclonal antibodies market in Europe is driven by strong public health infrastructure and proactive government policies that emphasize immuno-oncology innovation. Research funding through national and regional programs has strengthened the pipeline of monoclonal antibodies targeting solid tumors and hematological malignancies. In this context, the European Commission reports partnerships with nearly 630 organizations and a funding commitment of approximately USD 425 Million toward cancer prevention, detection, diagnosis, and treatment, strengthening Europe's immuno-oncology ecosystem. Clinical trial harmonization across countries is supporting faster regulatory assessments and multi-center study enrollments, facilitating product approval timelines. Additionally, a shift toward value-based healthcare is encouraging the adoption of therapies that offer high clinical benefits and long-term survival outcomes. Europe's focus on reducing hospitalizations through targeted outpatient biologic therapies has improved treatment adherence. Technological advances in biomanufacturing, continuous bioprocessing, and better post-marketing surveillance in integrated healthcare systems are enhancing production efficiency and cost reduction. Rising geriatric populations with complex cancer profiles demand tailored therapies.

ASIA PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS

The cancer monoclonal antibodies market in Asia Pacific is witnessing notable expansion, propelled by increased healthcare spending and rapid improvements in diagnostic capabilities. Public-private partnerships along with rising government expenditure on healthcare in the region are playing a vital role in establishing regional biopharmaceutical hubs, facilitating the local development and distribution of antibody-based cancer treatments. The Ministry of Health and Family Welfare in India, for instance, has been allocated approximately USD 11.98 Billion in the 2024-2025 budget, with USD 11.51 Billion designated for healthcare services and USD 467 Million for health research, signaling a substantial national commitment to advanced cancer care. An expanding middle class and growing healthcare literacy are driving demand for advanced, targeted therapies that minimize side effects. The integration of genomic profiling in oncology care is promoting personalized monoclonal antibody applications, while medical tourism and investments in cold chain infrastructure support market growth. Digital health platforms are improving treatment monitoring and adherence to monoclonal antibody regimens.

LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS

The Latin American market for cancer monoclonal antibodies is gaining momentum, fueled by improving oncology care infrastructure and expanding access to specialty treatment. It has been estimated that, in Brazil, an estimated 23.8% of men and 18.3% of women will develop cancer before the age of 75. Government initiatives aimed at modernizing cancer care protocols are driving the adoption of biologics in clinical settings. The region's rising cancer prevalence, especially among working-age populations, is boosting interest in therapies that improve quality of life and reduce hospital stays. Strategic international collaborations with academic and research institutions are enhancing local capacity for clinical trials and biological development.

MIDDLE EAST AND AFRICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS

In the Middle East and Africa, the cancer monoclonal antibodies market is expanding due to growing investments in oncology centers and enhanced access to specialty care. A recent report highlights that Saudi Arabia has committed USD 65 Billion to healthcare privatization, aiming to transform the country's entire healthcare landscape, an initiative that is expected to enhance cancer treatment infrastructure and access to advanced biologics. The region is witnessing an increase in public awareness campaigns that promote early cancer detection, creating demand for advanced biological treatments. Infrastructure development, including infusion clinics and diagnostic labs, is improving treatment accessibility. Educational initiatives targeting healthcare professionals are increasing familiarity with immunotherapy protocols, and facilitating clinical adoption.

COMPETITIVE LANDSCAPE:

The cancer monoclonal antibodies market is marked by fast-paced innovation, active pipeline expansion, and partnerships between biotech firms and research institutions. In January 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 Billion to boost its oncology pipeline, particularly with advanced antibody-drug conjugates like ARX517 for prostate cancer and additional candidates for HER2+ breast and renal cancers. Companies are focusing on antibody engineering to improve targeting and reduce side effects. Market competition is influenced by IP protection, regulatory pathways, biosimilar pressure, licensing deals, and geographic growth strategies. Strategic licensing agreements and regional expansions are also shaping the market dynamics. The cancer monoclonal antibodies market forecast projects sustained growth over the coming years, driven by rising cancer incidence, expanding therapeutic applications, and continued research in next-generation antibody therapies.

The report provides a comprehensive analysis of the competitive landscape in the cancer monoclonal antibodies market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • AbbVie Inc. (Abbott Laboratories)
  • AstraZeneca plc
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd. (Roche Holding AG)
  • Genmab A/S
  • Merck & Co., Inc.
  • Pfizer Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc. (Abbott Laboratories)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Biocon Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche Ltd. (Roche Holding AG)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Genmab A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co., Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2025
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2025
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2025
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million USD), 2026-2034
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million USD), 2026-2034
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players